Literature DB >> 11737774

Tailoring immunosuppressive therapy for renal transplant recipients.

Y F Vanrenterghem1.   

Abstract

During the past decade several new potent immunosuppressive agents with different modes of action and different side-effect profiles have become available. Nowadays immunosuppression after renal transplantation is no longer one single regimen applicable to all patients. In the selection of the optimal immunosuppressive protocol, individual drug-related toxicity, recipient-related risk factors as well as donor organ characteristics have to be taken into account. This article will give an overview of the most recently developed immunosuppressive agents available for clinical use. Their individual mode of action and their different efficacy and safety profile will be described as basis for selection of each of these drugs in an attempt to tailor the optimal therapeutic regimen for the individual patient both in terms of short-term and long-term outcome.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11737774     DOI: 10.1034/j.1399-3046.2001.00062.x

Source DB:  PubMed          Journal:  Pediatr Transplant        ISSN: 1397-3142


  3 in total

Review 1.  Interleukin 2 receptor antagonists for kidney transplant recipients.

Authors:  Angela C Webster; Lorenn P Ruster; Richard McGee; Sandra L Matheson; Gail Y Higgins; Narelle S Willis; Jeremy R Chapman; Jonathan C Craig
Journal:  Cochrane Database Syst Rev       Date:  2010-01-20

Review 2.  A benefit-risk assessment of basiliximab in renal transplantation.

Authors:  Ugo Boggi; Romano Danesi; Fabio Vistoli; Marco Del Chiaro; Stefano Signori; Piero Marchetti; Mario Del Tacca; Franco Mosca
Journal:  Drug Saf       Date:  2004       Impact factor: 5.606

3.  Monitoring cyclosporine absorption: a step beyond therapeutic drug monitoring.

Authors:  Po-Chang Lee
Journal:  Nephrourol Mon       Date:  2012-12-15
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.